Drug Approvals

MYQORZO™: A Promising New Treatment for Obstructive Hypertrophic Cardiomyopathy

MYQORZO™: A Promising New Treatment for Obstructive Hypertrophic Cardiomyopathy

What is it prescribed for? MYQORZO is used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This is a heart condition where the heart muscle becomes too thick and blocks blood flow out of the heart, making it hard to exercise or even do daily activities. It was approved by the FDA December 2025. MYQORZO is prescribed to help: Improve...

Rytelo Approved as a New Treatment Option for Myelodysplastic Syndromes

Rytelo Approved as a New Treatment Option for Myelodysplastic Syndromes

What is it prescribed for? RYTELO, approved on June 6, 2024, is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating...

CARDAMYST™: A Promising New Treatment for Sudden Episodes of Rapid Heart Rhythm (PSVT)

CARDAMYST™: A Promising New Treatment for Sudden Episodes of Rapid Heart Rhythm (PSVT)

What is it prescribed for? CARDAMYST is prescribed for adults who have sudden episodes of very fast heart rate called paroxysmal supraventricular tachycardia (PSVT). These episodes often start suddenly and can cause symptoms such as palpitations, dizziness, chest discomfort, or shortness of breath.  It was approved by the FDA December 2025. CARDAMYST is used to...

Livdelzi: a Breakthrough Treatment for Primary Biliary Cholangitis

Livdelzi: a Breakthrough Treatment for Primary Biliary Cholangitis

What is the name of the drug and what does it do? Approved on August 19, 2024, Livdelzi (pronounced liv-DEL-zee), generic name seladelpar, is a prescription medicine used to treat adults with primary biliary cholangitis (PBC), a chronic liver disease that damages the bile ducts. It is prescribed for people who do not respond well to the standard treatment,...

Imdelltra: A New Treatment for Extensive-Stage Small Cell Lung Cancer

Imdelltra: A New Treatment for Extensive-Stage Small Cell Lung Cancer

What is it prescribed for? IMDELLTRA, approved on May 16, 2024, is a bispecific delta-like ligand 3 (DLL3)-directed CD3 Tcell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.  What is the name of the drug and what does it do? Imdelltra...

Lumisight: An Innovative Optical Imaging Agent for Breast Cancer Surgery

Lumisight: An Innovative Optical Imaging Agent for Breast Cancer Surgery

What is it prescribed for? LUMISIGHT, approved on April 17, 2024, is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery.  What is the name of the drug and what does it do? Lumisight...